Research advances in cancer therapy of cisplatin liposome
- VernacularTitle:顺铂脂质体在肿瘤治疗中的研究进展
- Author:
Weixuan ZHAO
1
;
Xue LU
1
;
Ruilin ZHAO
2
;
Yanmei ZHANG
1
;
Ye YANG
1
;
Deying CAO
3
Author Information
1. Institute of New Materials and Advanced Manufacturing，Beijing Academy of Science and Technology，Beijing 100089，China
2. Hebei Fengtong Biotech Co. Ltd.，Shijiazhuang 050035，China
3. College of Pharmacy，Hebei Medical University，Shijiazhuang 050017，China
- Publication Type:Journal Article
- Keywords:
cisplatin;
liposome;
tumor;
co-delivery liposome;
stimuli-responsive liposome;
targeting liposome
- From:
China Pharmacy
2025;36(3):356-361
- CountryChina
- Language:Chinese
-
Abstract:
Chemotherapy based on cisplatin or its combination therapy is a common cancer treatment method. However， the non-specific side effects of cisplatin， poor pharmacokinetic properties of small molecule drugs， and susceptibility to drug resistance greatly limit the clinical application of cisplatin as first-line anti-tumor drug. With the development of nanocarrier technology， liposomes have become an ideal carrier for delivering cisplatin drugs due to their excellent properties of targeting， reducing toxicity， and enhancing efficacy. This paper reviews the status of cisplatin liposome both domestically and internationally which have entered clinical trials， including L-NDDP，SPI-077®， Lipoplatin®，LiPlaCis，SLIT and ILC， etc. Currently， only Lipoplatin® and ILC are showing good potential in cancer therapy. Although cisplatin liposome has made some progress in reducing systemic toxicity and improving treatment efficiency in clinical research， there is still potential for further improvement in tumor targeting and reducing side effects. In the future， more low-toxicity and efficient cisplatin liposomes can be developed through formulation technologies such as co-delivery liposome， stimuli-responsive liposome and targeting liposome.
